Twitxy Saved

drug hunter

Verified account This account is verified. Learn more

@drughunter_com

the science of drug discovery, distilled for industry innovators.
discover more by subscribing at: linktr.ee/drughunter
drughunter.com Joined March 2021
26 Following 11K Followers 1.5K Posts

Latest posts 5

Pinned post

drug hunter Verified account @drughunter_com
Genentech’s giredestrant (Wilserdly®), an oral SERD and estrogen receptor antagonist, has been FDA-approved in combination with the mTOR inhibitor everolimus for adults with ESR1-mutated, ER+/HER2− locally advanced or metastatic breast cancer.

Giredestrant is the fourth oral SERD to receive FDA approval, following Stemline’s elacestrant (Orserdu®), Lilly’s imlunestrant (Inluriyo®), and AstraZeneca’s camizestrant (Etcamah®).

The approval was supported by results from the Ph. 3 evERA trial. In patients with ESR1-mutated tumors, giredestrant plus everolimus reduced the risk of disease progression or death by 62% compared with standard endocrine therapy plus everolimus.

Genentech has also filed an NDA for giredestrant as adjuvant treatment for ER+/HER2− early-stage breast cancer. The FDA’s decision is expected by November 30.

Revisit our December 2025 case study to learn more about giredestrant’s discovery and development, along with the late-stage oral SERD competitive landscape.

Full article on Drug Hunter: drughunters.com/48s3MLe
1 replies 2 reposts 14 likes 1.5K views View on X
drug hunter Verified account @drughunter_com
Ascendis’ Weekly CNP Prodrug Navepegritide Gains FDA Approval for Achondroplasia | drughunters.com/3WJna3P

Ascendis Pharma’s navepegritide (Yuviwel®) has joined the growing list of targeted therapies for achondroplasia—and brings a notable dosing advantage: once-weekly administration.

The CNP prodrug uses Ascendis’ TransCon technology to overcome the notoriously short half-life of endogenous CNP, providing sustained exposure while counteracting the excessive FGFR3 signaling that drives achondroplasia.

In this Drug Hunter article, we explore:
• The FGFR3 biology underlying achondroplasia
• How CNP became a validated therapeutic strategy
• The peptide and PEG optimization behind navepegritide
• Clinical results supporting its FDA approval
• Ascendis’ combination strategy with its human growth hormone prodrug, lonapegsomatropin
• Emerging competition from oral FGFR inhibitors

See how peptide engineering turned a molecule with a half-life of only minutes into a once-weekly therapy. Read more on Drug Hunter: drughunters.com/3WJna3P
1 replies 5 reposts 30 likes 3.8K views View on X
drug hunter Verified account @drughunter_com
Novartis Discloses WIZ Degrader NVP-ITU512 for the Treatment of Sickle Cell Disease

Novartis’ James Manning disclosed the company’s CRBN-mediated molecular glue degrader of the WIZ transcription factor, NVP-ITU512 at the EFMC Medicinal Chemistry 2026 First Time Disclosures session in Basel, which detailed the team’s compromise between potency and a clean off-target profile for the treatment of a chronic illness in diverse patients with varied healthcare access.

From a phenotypic degradation screen in primary human erythroblasts derived from CD34+ cells, a medicinal chemistry optimization campaign focused on the development of two distinct series, with a premium placed on CRBN neosubstrate selectivity that led to prioritization of a novel CRBN-binding chemotype.

NVP-ITU512 demonstrates balanced potency and off-target profiles with desirable ADME properties, and the molecule progressed into clinical trials in 2024, where Novartis will likely attempt to position NVP-ITU512 as a universal oral therapy option for a globally diverse SCD patient population.

Members can read the full article here: drughunters.com/3XpGyTC
1 replies 5 reposts 36 likes 2.7K views View on X
drug hunter Verified account @drughunter_com
Bayer’s asundexian (Sunharbo®) has become the first factor XIa inhibitor to receive FDA approval. Approved in combination with antiplatelet therapy, it reduces stroke risk in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

In the Ph. 3 OCEANIC-STROKE trial, once-daily oral asundexian added to antiplatelet therapy reduced the relative risk of ischemic stroke by 26% compared with antiplatelet therapy alone. FXIa inhibitors have been a sought-after treatment option for secondary stroke prevention due to their potential to decouple therapeutic anticoagulation from increased bleeding risk, a common safety concern with DOACs (direct oral anticoagulants).

What did it take to discover and develop this first-in-class FXIa inhibitor? Revisit our April case study to explore asundexian’s discovery, development, and potential impact.

Members can read the full article on Drug Hunter: drughunters.com/3WosGsB